Tudor Investment Corp’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.91M Buy
71,836
+40,659
+130% +$4.07M 0.01% 965
2025
Q4
$3.03M Buy
31,177
+21,817
+233% +$1.87M 0.01% 1502
2025
Q3
$666K Buy
+9,360
New +$624K ﹤0.01% 2531
2025
Q2
Sell
-23,467
Closed -$1.23M 3493
2025
Q1
$1.23M Sell
23,467
-7,549
-24% -$424K ﹤0.01% 1680
2024
Q4
$1.71M Buy
31,016
+8,147
+36% +$429K 0.01% 1360
2024
Q3
$1.15M Buy
22,869
+17,820
+353% +$822K ﹤0.01% 1532
2024
Q2
$222K Buy
+5,049
New +$215K ﹤0.01% 2123
2024
Q1
Sell
-6,963
Closed -$331K 2479
2023
Q4
$331K Sell
6,963
-9,390
-57% -$395K ﹤0.01% 1990
2023
Q3
$726K Buy
16,353
+634
+4% +$29.5K 0.01% 1482
2023
Q2
$750K Buy
15,719
+6,817
+77% +$307K 0.01% 1480
2023
Q1
$350K Buy
+8,902
New +$324K 0.01% 1826

Other funds holding IRMD

Tudor Investment Corp's IRMD Position: Q1 2026 in Review

Tudor Investment Corp increased its iRadimed (IRMD) stake by 130% in Q1 2026, buying an estimated $4.07M and bringing the position to 71,836 shares worth $6.91M. The position accounts for 0.01% of the portfolio, ranked #965.

Tudor Investment Corp first reported a position in IRMD in Q1 2023 and has held it in 11 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Tudor Investment Corp held 71,836 shares of iRadimed worth $6.91M as of Q1 2026.
  • Tudor Investment Corp bought 40,659 iRadimed shares in Q1 2026, an estimated $4.07M.
  • iRadimed made up 0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #965 holding.
  • Tudor Investment Corp first reported a position in iRadimed in Q1 2023 and has held it in 11 quarters since.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.